Voyager Therapeutics (NASDAQ:VYGR) Upgraded at StockNews.com

Voyager Therapeutics (NASDAQ:VYGR) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Monday.

Several other analysts also recently issued reports on the company. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Wedbush cut their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Thursday. Leerink Partners started coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target for the company. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price target on shares of Voyager Therapeutics in a research note on Thursday. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $17.00.

Voyager Therapeutics Stock Down 9.3 %

Voyager Therapeutics stock opened at $5.64 on Monday. The firm has a market capitalization of $308.11 million, a PE ratio of 7.94 and a beta of 0.89. Voyager Therapeutics has a 52 week low of $5.59 and a 52 week high of $11.72. The firm’s 50-day simple moving average is $6.62 and its 200 day simple moving average is $7.49.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The business had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. During the same period last year, the company posted ($0.59) EPS. On average, research analysts expect that Voyager Therapeutics will post -1.12 EPS for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. grew its position in Voyager Therapeutics by 49.6% in the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after acquiring an additional 1,300 shares in the last quarter. Plato Investment Management Ltd acquired a new stake in Voyager Therapeutics during the 1st quarter valued at $38,000. China Universal Asset Management Co. Ltd. increased its stake in Voyager Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after buying an additional 4,098 shares during the period. SG Americas Securities LLC acquired a new position in Voyager Therapeutics in the 2nd quarter worth $85,000. Finally, ProShare Advisors LLC purchased a new position in Voyager Therapeutics in the 1st quarter valued at about $101,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.